Change in Pediatric Health Care Spending and Drug Utilization during the COVID-19 Pandemic

Lubrano, Riccardo; Giudice, Emanuela Del; Marcellino, Alessia; Ventriglia, Flavia; Dilillo, Anna; Luca, Enrica De; Mallardo, Saverio; Isoldi, Sara; Martucci, Vanessa; Sanseviero, Mariateresa; Iorfida, Donatella; Malvaso, Concetta; Cerimoniale, Giovanni; Ragni, Giuseppina; Grandinetti, Anna Lisa; Arenare, Loredana; Bloise, Silvia

doi:10.3390/children8121183

Cited by 7 publications

(3 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On 7 December 2021 the authorization was expanded to include children aged from 5 to 11 years [34][35][36][37]. Vaccinating this second age group could help, in association with the implementation of preventive measures in children [38][39][40][41], to mitigate downstream effects of the pandemic, such as social isolation and disruption of education, and allow for a return to normal life. However, the issue of vaccination in the pediatric age group has been very debated and there is still a lot of fear and perplexity among parents and pediatricians.…”

Section: Introductionmentioning

confidence: 99%

Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience

et al. 2022

Self Cite

View full text Add to dashboard Cite

Objective: Our aim was to evaluate the safety of COVID-19 vaccine in children resident in the Latina Local Health Authority. Methods: We conducted a telephone survey among children aged 5–11 years receiving BNT162b2 mRNA COVID-19 vaccine between December 15 and 21. The main outcomes included the presence of allergic reactions or anaphylaxis, adverse events after 24–48 h, 7 and 20 days of taking the first and second doses of medications, and documented SARS-CoV-2 infection after vaccination. The information obtained was automatically linked to a spreadsheet and analyzed. Results: 569 children were enrolled. The mean age was 114 ± 4.24 months; there were 251 males in the study. The vaccine showed a favorable safety profile; no anaphylaxis or serious adverse events were reported. The most common symptoms both after the first and second dose were injection site reactions, asthenia, and headache. Injection site reactions were more frequent after the first dose (p = 0.01), while systemic symptoms were more frequent after the second dose (p = 0.022). These symptoms were more frequent in patients with comorbidities (p = 0.0159). Conclusion: Our findings confirm the safety of COVID-19 vaccine in children younger 11 years and could be useful to promote its diffusion in pediatric ages in order to achieve “herd immunity” and prevent the virus’s circulation.

show abstract

Section: Introductionmentioning

confidence: 99%

Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Immunological treatments are the most promising tools to achieve clinical remission and improve quality of life in several diseases [ 45 ]. These choices also show promise from a healthcare system spending perspective [ 46 ].…”

Section: Discussionmentioning

confidence: 99%

Post-Infectious Acute Cerebellar Ataxia Treatment, a Case Report and Review of Literature

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background: infectious mononucleosis is very common during childhood and neurological manifestations are extremely rare. However, when they occur, an appropriate treatment must be undertaken to reduce morbidity and mortality as well as to ensure appropriate management. Methods: we describe the clinical and neurological records of a female patient with post-EBV acute cerebellar ataxia, whose symptoms rapidly resolved with intravenous immunoglobulin therapy. Afterwards, we compared our results with published data. Results: we reported the case of an adolescent female with a 5-day history of sudden asthenia, vomiting, dizziness, and dehydration, with a positive monospot test and hypertransaminasemia. In the following days, she developed acute ataxia, drowsiness, vertigo, and nystagmus with a positive EBV IgM titer, confirming acute infectious mononucleosis. The patient was clinically diagnosed with EBV-associated acute cerebellitis. A brain MRI showed no acute changes and a CT scan showed hepatosplenomegaly. She started therapy with acyclovir and dexamethasone. After a few days, because of her condition’s deterioration, she received intravenous immunoglobulin and demonstrated a good clinical response. Conclusions: although there are no consensus guidelines for the treatment of post-infectious acute cerebellar ataxia, early intervention with intravenous immunoglobulin might prevent adverse outcomes, especially in cases that do not respond to high-dose steroid therapy.

show abstract

“…It is challenging to differentiate recurrent fevers related to autoinflammatory disorders and those related to recurrent viral infections, particularly for young children in a childcare or school setting (1). The onset of the COVID-19 pandemic in North America in March 2020 presented an unusual situation with a novel infectious entity, an increased level of concern for fevers, as well as decreased exposure of children to common infections during a time of increased isolation and masking (2)(3)(4). Daily life for the vast majority of children with rheumatic diseases was impacted with quarantining (5).…”

Section: Introductionmentioning

confidence: 99%

Increase in pediatric recurrent fever evaluations during the first year of the COVID-19 pandemic in North America

Mansfield,

Lapidus,

Romero

et al. 2023

Front. Pediatr.

View full text Add to dashboard Cite

The impact of the COVID-19 pandemic on new diagnoses of recurrent fevers and autoinflammatory diseases is largely unknown. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) PFAPA/AID Working Group aimed to investigate the impact of the COVID-19 pandemic on the number of pediatric patients evaluated for recurrent fevers and autoinflammatory diseases in North America. The absolute number of new outpatient visits and the proportion of these visits attributed to recurrent fever diagnoses during the pre-pandemic period (1 March 2019–29 February 2020) and the first year of the COVID-19 pandemic (1 March 2020–28 February 2021) were examined. Data were collected from 27 sites in the United States and Canada. Our results showed an increase in the absolute number of new visits for recurrent fever evaluations in 21 of 27 sites during the COVID-19 pandemic compared to the pre-pandemic period. The increase was observed across different geographic regions in North America. Additionally, the proportion of new visits to these centers for recurrent fever in relation to all new patient evaluations was significantly higher during the first year of the pandemic, increasing from 7.8% before the pandemic to 10.9% during the pandemic year (p < 0.001). Our findings showed that the first year of the COVID-19 pandemic was associated with a higher number of evaluations by pediatric subspecialists for recurrent fevers. Further research is needed to understand the reasons behind these findings and to explore non-infectious triggers for recurrent fevers in children.

show abstract

Change in Pediatric Health Care Spending and Drug Utilization during the COVID-19 Pandemic

Cited by 7 publications

References 52 publications

Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience

Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience

Post-Infectious Acute Cerebellar Ataxia Treatment, a Case Report and Review of Literature

Increase in pediatric recurrent fever evaluations during the first year of the COVID-19 pandemic in North America

Contact Info

Product

Resources

About